Comparative Pharmacology
Head-to-head clinical analysis: DEXAMETHASONE SODIUM PHOSPHATE versus KENALOG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAMETHASONE SODIUM PHOSPHATE versus KENALOG.
DEXAMETHASONE SODIUM PHOSPHATE vs KENALOG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone sodium phosphate is a glucocorticoid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating gene expression.
Triamcinolone acetonide is a synthetic corticosteroid with potent glucocorticoid and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins and leukotrienes. It also suppresses cytokine production and immune cell migration.
4-20 mg IV or IM every 4-6 hours; for cerebral edema: 10 mg IV followed by 4 mg IM/IV every 6 hours; for shock: 20 mg IV initially then 2-6 mg/kg IV bolus or 40 mg IV every 2-6 hours as needed.
Kenalog (triamcinolone acetonide) 40-80 mg intramuscularly (deep gluteal) every 4 weeks; or 0.5-1 mg/kg intravenously every 24 hours (for acute conditions).
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in adults; however, the duration of action extends beyond the plasma half-life due to intracellular receptor-mediated effects.
Terminal half-life ~2-5 hours (triamcinolone acetonide); clinical duration prolonged due to crystalline depot formulation
Renal excretion of unchanged drug and metabolites accounts for approximately 60-70% of elimination; biliary/fecal excretion accounts for 30-40%.
Renal (primarily as metabolites), ~30% unchanged; biliary/fecal minor (≤10%)
Category D/X
Category C
Corticosteroid
Corticosteroid